Ipamorelin: A Research Overview of the Selective Ghrelin-Receptor Agonist

Ipamorelin sits on the ghrelin receptor side of the growth hormone secretagogue family — the same side as GHRP-2 and GHRP-6 — but it is defined by one property that sets it apart from its relatives: selectivity. While older GHRPs stimulate growth hormone and also raise cortisol, prolactin, and appetite, ipamorelin was specifically engineered to release GH with minimal off-target hormonal effects. That “clean” profile is its entire identity and the reason it became the modern default ghrelin-pathway partner in combination research.

This overview summarizes what the published literature reports about Ipamorelin — its structure, mechanism, the selectivity that distinguishes it, its evidence base, why it is paired with GHRH analogs, and its regulatory and anti-doping status. It describes findings as they appeared in their study systems. It is not dosing guidance, medical advice, or a recommendation for use.

What Ipamorelin Is

Ipamorelin is a synthetic pentapeptide in the growth hormone secretagogue class. Like GHRP-2 and GHRP-6, it acts on the ghrelin receptor — but it was developed as a more selective agonist, and that selectivity is the point of the molecule. It is short-acting, producing a pulse-like GH release.

Mechanism — Selective Ghrelin-Receptor Activation

Ipamorelin is an agonist at the growth hormone secretagogue receptor GHS-R1a — the ghrelin receptor — on pituitary somatotroph cells, triggering pulsatile GH release. The defining finding came from Raun and colleagues in 1998: ipamorelin stimulates GH release without producing significant elevations in ACTH, cortisol, or prolactin, distinguishing it from GHRP-2 and hexarelin, which activate additional pathways that raise those hormones (Raun et al., Eur J Endocrinol 1998). In practical research terms, ipamorelin is the “clean” ghrelin receptor secretagogue: it isolates the GH-releasing effect without the appetite surge and stress-hormone elevations associated with the older GHRPs.

This selectivity also makes it the preferred agent for combination research targeting the ghrelin pathway. Because GHRH-receptor agonists and ghrelin-receptor agonists work through complementary, synergistic pathways, pairing a GHRH analog with ipamorelin produces a larger combined GH pulse than either alone, with ipamorelin contributing the ghrelin-pathway component without the off-target effects (synergy and combination rationale).

The Evidence Base

Ipamorelin has a foundational pharmacology literature, anchored by the Raun characterization and situated within the broader, peer-reviewed history of growth hormone secretagogues that reached clinical study (Ishida et al. GHS review). Its selective profile is well-documented at the pharmacological level.

The limit is the familiar one: the evidence establishes ipamorelin’s receptor selectivity and acute GH-releasing pharmacology, not a large, long-term efficacy-and-safety program for body-composition, recovery, or anti-aging use in healthy adults. It is not FDA-approved for any indication.

• Ipamorelin’s selective GH release (without significant cortisol/prolactin/appetite effects) is well-characterized pharmacologically.
• Its clean profile makes it the modern default ghrelin-pathway partner in GHRH-plus-GHRP combination research.
• Evidence supports acute pharmacology and selectivity, not long-term efficacy or safety for wellness use.

Safety Considerations

Ipamorelin’s selectivity gives it a cleaner secondary-hormone profile than GHRP-2 or GHRP-6 — with less appetite stimulation and minimal cortisol and prolactin elevations — which is a genuine advantage for controlled research. But the core GH-axis caution still applies: ipamorelin raises GH and IGF-1, which are mitogenic (growth-promoting) signals, so the standard caution against use with active or prior malignancy applies here as it does to the whole class. A favorable secondary hormone profile does not eliminate the GH/IGF-1 considerations.

Regulatory and Anti-Doping Status

The status below reflects mid-2026 and may change; verify before relying on it. Ipamorelin is not FDA-approved for any indication. Like CJC-1295, it has been caught up in the FDA’s evolving 503A peptide-compounding review, and its compounding status has shifted during 2026; any reclassification permitting compounding would still not equal FDA drug approval. Material sold by research suppliers is for laboratory use only and, by its labeling, not for human consumption. As a growth hormone secretagogue, ipamorelin is prohibited in sport by the World Anti-Doping Agency (Category S2).

Why Ipamorelin Draws Research Interest

Ipamorelin is the selective tool among the ghrelin receptor secretagogues — the one that isolates GH release from the appetite and stress-hormone effects of the older GHRPs — which makes it both a clean experimental probe and the standard ghrelin-pathway partner in combination studies. The accurate framing is a well-characterized, selective GHS-R1a agonist with solid foundational pharmacology, a cleaner secondary-hormone profile than its GHRP relatives, the same underlying GH/IGF-1 safety considerations, no FDA approval, and a clear anti-doping prohibition.

For deeper reading, the cited literature is the best starting point. Ipamorelin is most often studied alongside a GHRH analog — see the CJC-1295 and ipamorelin combination overview — and the related GHRP-2, GHRP-6, Sermorelin, and Tesamorelin overviews complete the picture. The wider class is in our peptide research library.